EGFR and non-small cell lung carcinoma: Minhua Wu’s study demonstrated that cancer-associated fibroblasts (CAFs) promoted epithelial-mesenchymal transition (EMT) and resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) by secreting hepatocyte growth factor (HGF) and insulin-like growth factor 1 (IGF-1) to activate ANXA2 (35).